GBS Venture Partners

Moximed, Inc. is a medical technology company based in Hayward, California, that focuses on developing innovative treatments for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain associated with medial compartment knee osteoarthritis, allowing patients to maintain high levels of activity. Additionally, Moximed has developed the MISHA Knee System, which provides an outpatient treatment option for individuals who have not responded to conventional therapies and are not suitable candidates for knee replacement surgery. By minimizing joint pain and providing dynamic load reduction, Moximed's implants aim to improve the standard of care and enhance the quality of life for patients, potentially delaying or avoiding the need for more invasive surgical interventions. Moximed has been operational since its incorporation in 2006, serving patients and medical professionals globally.

Moximed, Inc. is a medical technology company based in Hayward, California, that focuses on developing innovative treatments for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain associated with medial compartment knee osteoarthritis, allowing patients to maintain high levels of activity. Additionally, Moximed has developed the MISHA Knee System, which provides an outpatient treatment option for individuals who have not responded to conventional therapies and are not suitable candidates for knee replacement surgery. By minimizing joint pain and providing dynamic load reduction, Moximed's implants aim to improve the standard of care and enhance the quality of life for patients, potentially delaying or avoiding the need for more invasive surgical interventions. Moximed has been operational since its incorporation in 2006, serving patients and medical professionals globally.

Moximed, Inc. is a medical technology company based in Hayward, California, that focuses on developing innovative treatments for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain associated with medial compartment knee osteoarthritis, allowing patients to maintain high levels of activity. Additionally, Moximed has developed the MISHA Knee System, which provides an outpatient treatment option for individuals who have not responded to conventional therapies and are not suitable candidates for knee replacement surgery. By minimizing joint pain and providing dynamic load reduction, Moximed's implants aim to improve the standard of care and enhance the quality of life for patients, potentially delaying or avoiding the need for more invasive surgical interventions. Moximed has been operational since its incorporation in 2006, serving patients and medical professionals globally.

Moximed, Inc. is a medical technology company based in Hayward, California, that focuses on developing innovative treatments for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain associated with medial compartment knee osteoarthritis, allowing patients to maintain high levels of activity. Additionally, Moximed has developed the MISHA Knee System, which provides an outpatient treatment option for individuals who have not responded to conventional therapies and are not suitable candidates for knee replacement surgery. By minimizing joint pain and providing dynamic load reduction, Moximed's implants aim to improve the standard of care and enhance the quality of life for patients, potentially delaying or avoiding the need for more invasive surgical interventions. Moximed has been operational since its incorporation in 2006, serving patients and medical professionals globally.

Elastagen is a clinical-stage medical company focused on developing products based on human protein tropoelastin, a vital component for tissues that require elasticity, such as skin and blood vessels. The company has created a synthetic version of elastin that mirrors the natural protein found in the human body, allowing for innovative applications in skin rejuvenation, scar remodeling, and tissue repair. Elastagen's offerings include injectable synthetic human elastin and chemically cross-linked tropoelastin for aesthetic purposes, aimed at helping patients maintain skin elasticity and suppleness. Founded through the acquisition of intellectual property from research conducted by Prof Weiss at the University of Sydney, Elastagen has attracted significant investment from both Australian and international life science venture capital groups. Its operations have grown from Australia to include production facilities in Europe and clinical activities in the UK.

Moximed, Inc. is a medical technology company based in Hayward, California, that focuses on developing innovative treatments for patients with knee osteoarthritis. The company offers the Atlas System, an implantable joint unloader designed to alleviate pain associated with medial compartment knee osteoarthritis, allowing patients to maintain high levels of activity. Additionally, Moximed has developed the MISHA Knee System, which provides an outpatient treatment option for individuals who have not responded to conventional therapies and are not suitable candidates for knee replacement surgery. By minimizing joint pain and providing dynamic load reduction, Moximed's implants aim to improve the standard of care and enhance the quality of life for patients, potentially delaying or avoiding the need for more invasive surgical interventions. Moximed has been operational since its incorporation in 2006, serving patients and medical professionals globally.

Ivantis Inc. is a medical device company based in Irvine, California, focused on developing innovative treatments for primary open-angle glaucoma. Founded in 2007, the company has created a minimally invasive intracanalicular scaffold that helps alleviate high intraocular pressure by restoring the natural drainage pathway in Schlemm's canal. This device aims to provide a less invasive and more effective solution for the over 60 million individuals worldwide affected by this condition. In addition to its glaucoma treatments, Ivantis plans to expand its research and development efforts to address other challenging diseases within the field of ophthalmology. The company's products are utilized in clinical trials by ophthalmology specialists across the United States.

AirXpanders, Inc. was a medical device company headquartered in San Jose, California, specializing in the design, manufacture, sale, and distribution of innovative medical devices aimed at improving breast reconstruction outcomes. Founded in 2005, the company developed the AeroForm Tissue Expander System, a needle-free and patient-controlled device specifically designed for use in two-stage breast reconstruction following mastectomy. This system allowed patients to expand tissue in a controlled manner before the insertion of breast implants. Despite its advancements in medical technology, AirXpanders filed for Chapter 7 bankruptcy and ceased operations on September 25, 2019.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Neurovance, Inc. is a clinical-stage neuroscience company headquartered in Cambridge, Massachusetts, focused on developing and commercializing therapies for attention deficit hyperactivity disorder (ADHD) in both adults and children. Founded in 2009, Neurovance has developed centanafadine, a triple reuptake inhibitor that precisely modulates the activity of norepinephrine, dopamine, and serotonin to enhance focus and address symptoms of inattention and disorganization in ADHD patients. As of 2017, Neurovance operates as a subsidiary of Otsuka America, Inc.

Ivantis Inc. is a medical device company based in Irvine, California, focused on developing innovative treatments for primary open-angle glaucoma. Founded in 2007, the company has created a minimally invasive intracanalicular scaffold that helps alleviate high intraocular pressure by restoring the natural drainage pathway in Schlemm's canal. This device aims to provide a less invasive and more effective solution for the over 60 million individuals worldwide affected by this condition. In addition to its glaucoma treatments, Ivantis plans to expand its research and development efforts to address other challenging diseases within the field of ophthalmology. The company's products are utilized in clinical trials by ophthalmology specialists across the United States.

AirXpanders, Inc. was a medical device company headquartered in San Jose, California, specializing in the design, manufacture, sale, and distribution of innovative medical devices aimed at improving breast reconstruction outcomes. Founded in 2005, the company developed the AeroForm Tissue Expander System, a needle-free and patient-controlled device specifically designed for use in two-stage breast reconstruction following mastectomy. This system allowed patients to expand tissue in a controlled manner before the insertion of breast implants. Despite its advancements in medical technology, AirXpanders filed for Chapter 7 bankruptcy and ceased operations on September 25, 2019.

Hydrexia is an Australian company that has successfully designed, built, and tested systems that stores hydrogen in solid form, based on a proprietary magnesium alloy.

Neurovance, Inc. is a clinical-stage neuroscience company headquartered in Cambridge, Massachusetts, focused on developing and commercializing therapies for attention deficit hyperactivity disorder (ADHD) in both adults and children. Founded in 2009, Neurovance has developed centanafadine, a triple reuptake inhibitor that precisely modulates the activity of norepinephrine, dopamine, and serotonin to enhance focus and address symptoms of inattention and disorganization in ADHD patients. As of 2017, Neurovance operates as a subsidiary of Otsuka America, Inc.

Ocunexus Therapeutics is a biopharmaceutical company based in San Diego, California, that develops treatments for unmet clinical needs in ophthalmology. It focuses on drug candidates using a novel mechanism called Gap Junction Channel Modulation, targeting both front- and back-of-the-eye diseases. The technology may also be applicable to other acute and chronic conditions. Previously known as CoDa Therapeutics, the firm originally concentrated on wound care therapeutics using gap junction modulation.

Hatchtech is an Australian company focused on developing a proprietary technology platform aimed at creating low-toxicity pest control products. The company's patented technology offers a novel mode of action that effectively blocks the hatching of pest species' eggs, making it applicable for managing ectoparasites and other egg-laying pests affecting humans, animals, crops, and built environments. Hatchtech also provides a specialized pharmaceutical product that delivers a single-dose, topical treatment designed to eliminate head lice infestations by killing both the lice and their eggs in one application. Through its innovative approaches, Hatchtech seeks to advance pest control solutions with reduced environmental impact.

AirXpanders, Inc. was a medical device company headquartered in San Jose, California, specializing in the design, manufacture, sale, and distribution of innovative medical devices aimed at improving breast reconstruction outcomes. Founded in 2005, the company developed the AeroForm Tissue Expander System, a needle-free and patient-controlled device specifically designed for use in two-stage breast reconstruction following mastectomy. This system allowed patients to expand tissue in a controlled manner before the insertion of breast implants. Despite its advancements in medical technology, AirXpanders filed for Chapter 7 bankruptcy and ceased operations on September 25, 2019.

Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.

Celladon Corporation, established in 2000 and headquartered in La Jolla, California, is a biotechnology company focused on developing molecular therapies for treating heart failure. The company's primary product candidate is MYDICAR, an enzyme replacement therapy aimed at addressing the key enzyme deficiency in advanced heart failure. This therapy targets SERCA2a, an enzyme crucial for regulating calcium cycling and contractility in heart muscle cells.

AirXpanders, Inc. was a medical device company headquartered in San Jose, California, specializing in the design, manufacture, sale, and distribution of innovative medical devices aimed at improving breast reconstruction outcomes. Founded in 2005, the company developed the AeroForm Tissue Expander System, a needle-free and patient-controlled device specifically designed for use in two-stage breast reconstruction following mastectomy. This system allowed patients to expand tissue in a controlled manner before the insertion of breast implants. Despite its advancements in medical technology, AirXpanders filed for Chapter 7 bankruptcy and ceased operations on September 25, 2019.

Xenome is a progressive Australian biotechnology company with a promising and distinctive technology platform targeting pain and inflammation. Xen2174, the Company's lead drug candidate is currently completing a Phase 1b/2a clinical trial for cancer pain with evidence to date providing strong support that the trial endpoints will be successfully met. More substantive clinical trials for expanded indications are planned for 2008. In addition, the drug discovery platform from which Xen2174 emerged has inherent value due to its ability to repeatedly identify new lead medicinal compounds on the basis of its unique construction around Australian biodiversity. Specifically, Xenome has generated a unique expertise in peptide chemistry to translate the evolutionary advantages inherent in venom peptides into highly bioactive libraries of molecules that are of interest to global biotechnology and pharmaceutical companies.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Pathway Therapeutics is focused on the discovery and development of best in class isoform selective inhibitors of PI3-kinase (PI3K) for the treatment of cancer and inflammatory diseases in targeted patient populations most likely to benefit.

Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined product portfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need. Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities. Verva has subsequently engaged expert scientists, clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy.

Ocunexus Therapeutics is a biopharmaceutical company based in San Diego, California, that develops treatments for unmet clinical needs in ophthalmology. It focuses on drug candidates using a novel mechanism called Gap Junction Channel Modulation, targeting both front- and back-of-the-eye diseases. The technology may also be applicable to other acute and chronic conditions. Previously known as CoDa Therapeutics, the firm originally concentrated on wound care therapeutics using gap junction modulation.

Euthymics Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics targeting central nervous system disorders. Founded in 2009, the company aims to address significant unmet medical needs, particularly in the areas of major depressive disorder (MDD) and alcohol use disorder (AUD). Euthymics is developing EB-1010, a treatment for depression designed to enhance efficacy while minimizing common side effects associated with standard antidepressants, such as weight gain and sexual dysfunction. Additionally, the company is working on therapies for smoking cessation and impulsivity, targeting patients experiencing withdrawal symptoms and cravings. Through its research and development efforts, Euthymics Bioscience seeks to improve the quality of life for individuals struggling with these challenging conditions.

AirXpanders, Inc. was a medical device company headquartered in San Jose, California, specializing in the design, manufacture, sale, and distribution of innovative medical devices aimed at improving breast reconstruction outcomes. Founded in 2005, the company developed the AeroForm Tissue Expander System, a needle-free and patient-controlled device specifically designed for use in two-stage breast reconstruction following mastectomy. This system allowed patients to expand tissue in a controlled manner before the insertion of breast implants. Despite its advancements in medical technology, AirXpanders filed for Chapter 7 bankruptcy and ceased operations on September 25, 2019.

Hatchtech is an Australian company focused on developing a proprietary technology platform aimed at creating low-toxicity pest control products. The company's patented technology offers a novel mode of action that effectively blocks the hatching of pest species' eggs, making it applicable for managing ectoparasites and other egg-laying pests affecting humans, animals, crops, and built environments. Hatchtech also provides a specialized pharmaceutical product that delivers a single-dose, topical treatment designed to eliminate head lice infestations by killing both the lice and their eggs in one application. Through its innovative approaches, Hatchtech seeks to advance pest control solutions with reduced environmental impact.

AiMedics is a medical device company focused on developing solutions for managing hypoglycemia, particularly during the night. Its primary product, the HypoMon, is a non-invasive alarm system designed to detect nighttime hypoglycemia in children and young adults aged 10 to 25 with type 1 diabetes. This device alerts both patients and their caregivers, helping to improve safety and health outcomes. AiMedics serves a diverse clientele, including caregivers, patients, and healthcare professionals across the United States, Europe, Australia, and New Zealand. Founded in 2001, the company is headquartered in Eveleigh, Australia, and maintains an additional office in Warwick, United Kingdom.

NeuroVista Corporation is a medical device company based in Seattle, Washington, focused on developing innovative technologies for the management and treatment of epilepsy in the United States. Founded in 2002 and originally known as BioNeuronics Corporation until its rebranding in 2007, NeuroVista aims to address the challenges faced by the approximately 3 million Americans living with epilepsy, a neurological condition characterized by unpredictable seizures. These seizures can vary significantly in severity and impact daily life, affecting individuals primarily between the ages of 15 and 64. Through its advisory technologies, NeuroVista seeks to provide tools that help mitigate the uncertainty surrounding the timing of epileptic seizures, ultimately improving the quality of life for those affected by this condition.

Nuon Therapeutics is focused on the development and commercialization of new therapies in inflammation and neurological diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS) and neuropathic pain.

Pathway Therapeutics is focused on the discovery and development of best in class isoform selective inhibitors of PI3-kinase (PI3K) for the treatment of cancer and inflammatory diseases in targeted patient populations most likely to benefit.

Euthymics Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics targeting central nervous system disorders. Founded in 2009, the company aims to address significant unmet medical needs, particularly in the areas of major depressive disorder (MDD) and alcohol use disorder (AUD). Euthymics is developing EB-1010, a treatment for depression designed to enhance efficacy while minimizing common side effects associated with standard antidepressants, such as weight gain and sexual dysfunction. Additionally, the company is working on therapies for smoking cessation and impulsivity, targeting patients experiencing withdrawal symptoms and cravings. Through its research and development efforts, Euthymics Bioscience seeks to improve the quality of life for individuals struggling with these challenging conditions.

Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.

AirXpanders, Inc. was a medical device company headquartered in San Jose, California, specializing in the design, manufacture, sale, and distribution of innovative medical devices aimed at improving breast reconstruction outcomes. Founded in 2005, the company developed the AeroForm Tissue Expander System, a needle-free and patient-controlled device specifically designed for use in two-stage breast reconstruction following mastectomy. This system allowed patients to expand tissue in a controlled manner before the insertion of breast implants. Despite its advancements in medical technology, AirXpanders filed for Chapter 7 bankruptcy and ceased operations on September 25, 2019.

Viveve Medical, Inc., established in 2005, specializes in designing, developing, manufacturing, and marketing medical devices for non-invasive treatment of women's health issues. Its primary product, the Viveve System, employs radiofrequency technology to address vaginal laxity, improve sexual function, and treat stress urinary incontinence. The company's products are sold through its own sales team and distributors in various regions worldwide, including the US, Europe, Asia Pacific, and Latin America. Viveve Medical is headquartered in Englewood, Colorado.

Xenome is a progressive Australian biotechnology company with a promising and distinctive technology platform targeting pain and inflammation. Xen2174, the Company's lead drug candidate is currently completing a Phase 1b/2a clinical trial for cancer pain with evidence to date providing strong support that the trial endpoints will be successfully met. More substantive clinical trials for expanded indications are planned for 2008. In addition, the drug discovery platform from which Xen2174 emerged has inherent value due to its ability to repeatedly identify new lead medicinal compounds on the basis of its unique construction around Australian biodiversity. Specifically, Xenome has generated a unique expertise in peptide chemistry to translate the evolutionary advantages inherent in venom peptides into highly bioactive libraries of molecules that are of interest to global biotechnology and pharmaceutical companies.

Nuon Therapeutics is focused on the development and commercialization of new therapies in inflammation and neurological diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS) and neuropathic pain.

Nuwellis develops, manufactures, and markets ultrafiltration therapy devices to treat fluid overload. Its Aquadex system family—the FlexFlow and SmartFlow systems—removes excess fluid from patients who have not responded to medical management such as diuretics, in both adults and children.

Pathway Therapeutics is focused on the discovery and development of best in class isoform selective inhibitors of PI3-kinase (PI3K) for the treatment of cancer and inflammatory diseases in targeted patient populations most likely to benefit.

Founded in 2004, Applied Physiology develops and commercializes treatment guidance systems intended to transform the care of critically-ill patients. The company's main focus is on real-time circulation management with its Navigator™ product. Applied Physiology has offices in Australia and the United Kingdom.

Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined product portfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need. Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities. Verva has subsequently engaged expert scientists, clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy.

Humanigen, Inc. is a clinical-stage biopharmaceutical company based in Burlingame, California, that specializes in the development of proprietary monoclonal antibodies aimed at immunotherapy and oncology treatments. The company’s leading candidate, Lenzilumab, targets granulocyte-macrophage colony-stimulating factor and is currently undergoing Phase Ib/II clinical trials for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. Additionally, Humanigen is developing Ifabotuzumab, which targets the EphA3 receptor and has completed the Phase I portion of a Phase I/II clinical trial for various hematologic malignancies. The company is also working on HGEN005, an anti-EMR1 monoclonal antibody in the pre-clinical stage for eosinophilic diseases. Humanigen has established collaborations, including a clinical partnership with Kite Pharma to study Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma and a research agreement with the Department of Defense to facilitate the development of Lenzilumab for potential emergency use in COVID-19. Formed in 2000, the company was previously known as KaloBios Pharmaceuticals and rebranded as Humanigen in 2017.

Humanigen, Inc. is a clinical-stage biopharmaceutical company based in Burlingame, California, that specializes in the development of proprietary monoclonal antibodies aimed at immunotherapy and oncology treatments. The company’s leading candidate, Lenzilumab, targets granulocyte-macrophage colony-stimulating factor and is currently undergoing Phase Ib/II clinical trials for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. Additionally, Humanigen is developing Ifabotuzumab, which targets the EphA3 receptor and has completed the Phase I portion of a Phase I/II clinical trial for various hematologic malignancies. The company is also working on HGEN005, an anti-EMR1 monoclonal antibody in the pre-clinical stage for eosinophilic diseases. Humanigen has established collaborations, including a clinical partnership with Kite Pharma to study Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma and a research agreement with the Department of Defense to facilitate the development of Lenzilumab for potential emergency use in COVID-19. Formed in 2000, the company was previously known as KaloBios Pharmaceuticals and rebranded as Humanigen in 2017.

KaloBios Pharmaceuticals provides medicines for respiratory diseases and certain cancers. The company is a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases. They designed to overcome marketed antibody products.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Peplin is a development-stage specialty pharmaceutical company dedicated to advancing medical dermatology products. The company focuses on PEP005, a compound derived from Euphorbia peplus, which is utilized in its lead product, a patient-applied topical gel currently in Phase III clinical trials for the treatment of actinic keratosis. Additionally, Peplin is developing a physician-applied topical gel for superficial basal cell carcinoma, also based on PEP005. The active ingredient in both products is a small molecule extracted and purified from the sap of Euphorbia peplus. Peplin's commitment to addressing skin disorders is further underscored by its acquisition of Neosil, Inc., a dermatology-focused company, before eventually being acquired by LEO Pharma A/S.

Xenome is a progressive Australian biotechnology company with a promising and distinctive technology platform targeting pain and inflammation. Xen2174, the Company's lead drug candidate is currently completing a Phase 1b/2a clinical trial for cancer pain with evidence to date providing strong support that the trial endpoints will be successfully met. More substantive clinical trials for expanded indications are planned for 2008. In addition, the drug discovery platform from which Xen2174 emerged has inherent value due to its ability to repeatedly identify new lead medicinal compounds on the basis of its unique construction around Australian biodiversity. Specifically, Xenome has generated a unique expertise in peptide chemistry to translate the evolutionary advantages inherent in venom peptides into highly bioactive libraries of molecules that are of interest to global biotechnology and pharmaceutical companies.

Pathway Therapeutics is focused on the discovery and development of best in class isoform selective inhibitors of PI3-kinase (PI3K) for the treatment of cancer and inflammatory diseases in targeted patient populations most likely to benefit.

NovaSys Health is a prominent provider of managed healthcare services, operating one of the largest health plans in Arkansas. With approximately 11,000 contracted providers in the region and over 4,300 in Arkansas, the company emphasizes strong relationships with healthcare providers. It offers a range of health plans and related services, including customized solutions, provider relations, and eligibility and billing administration, catering to a diverse network of hospitals, physicians, and ancillary providers.

$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

Nuon Therapeutics is focused on the development and commercialization of new therapies in inflammation and neurological diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS) and neuropathic pain.

As of October 2010, Phenomix closed down as it was unable to find a partner to pay for is clinical trial bills after Forest Laboratories walked away. Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases. Phenomix' lead clinical candidate, PHX1149, is a DPP4 inhibitor in phase 2 testing as a once daily oral treatment for type 2 diabetes. Phenomix' second program is directed at the treatment of hepatitis C through inhibition of the NS3/4A viral protease. Phenomix is based in San Diego, California.

ChemGenex Pharmaceuticals Ltd is an integrated biopharmaceutical company focused on the discovery and development of oncology drugs. Founded in 1958 and based in Geelong, Australia, the company is engaged in creating small molecule therapeutics that target significant unmet medical needs in cancer treatment. Its lead product candidate, omacetaxine mepesuccinate, is currently undergoing Phase 2/3 clinical trials for chronic myelogenous leukemia and Phase 2 trials for acute myelogenous leukemia and myelodysplastic syndrome. Additionally, ChemGenex is developing Quinamed, which is in Phase 2 clinical trials for hormone refractory prostate cancer. The company aims to address critical therapeutic gaps in oncology and other areas, including diabetes and depression, through innovative approaches and new mechanisms of action in its drug development pipeline.

Proacta Inc. is a private, clinical-stage, biopharmaceutical company headquartered in San Diego, California. They are focused on addressing unmet needs in the field of cancer with the development of hypoxia-activated prodrugs that target cancer cells. Proacta was founded on intellectual property generated in New Zealand at the University of Auckland and in the United States at Stanford University. Proacta's patent family covers a series of hypoxia-activated prodrugs designed to treat cancer. Expansion of this portfolio is supported by ongoing research at The University of Auckland. PR610 is the lead compound from their pipeline of pro-drugs based on hypoxia-activated tyrosine-kinase inhibitors. These pro-drugs selectively release active tyrosine-kinase inhibitors within the low-oxygen (hypoxic) environment found in many solid tumors. By shifting the release of active drug away from normal tissues and into cancer tissues, these drugs are predicted to be more effective and less toxic than currently available therapies. To date, Proacta has raised $43 million in two private financings. Investors include Alta Partners, Clarus Ventures, Delphi Ventures, Endeavour Capital (New Zealand), GBS Venture Partners (Australia), Genentech, No 8 Ventures (New Zealand) and Roche.

Ocunexus Therapeutics is a biopharmaceutical company based in San Diego, California, that develops treatments for unmet clinical needs in ophthalmology. It focuses on drug candidates using a novel mechanism called Gap Junction Channel Modulation, targeting both front- and back-of-the-eye diseases. The technology may also be applicable to other acute and chronic conditions. Previously known as CoDa Therapeutics, the firm originally concentrated on wound care therapeutics using gap junction modulation.

Proacta Inc. is a private, clinical-stage, biopharmaceutical company headquartered in San Diego, California. They are focused on addressing unmet needs in the field of cancer with the development of hypoxia-activated prodrugs that target cancer cells. Proacta was founded on intellectual property generated in New Zealand at the University of Auckland and in the United States at Stanford University. Proacta's patent family covers a series of hypoxia-activated prodrugs designed to treat cancer. Expansion of this portfolio is supported by ongoing research at The University of Auckland. PR610 is the lead compound from their pipeline of pro-drugs based on hypoxia-activated tyrosine-kinase inhibitors. These pro-drugs selectively release active tyrosine-kinase inhibitors within the low-oxygen (hypoxic) environment found in many solid tumors. By shifting the release of active drug away from normal tissues and into cancer tissues, these drugs are predicted to be more effective and less toxic than currently available therapies. To date, Proacta has raised $43 million in two private financings. Investors include Alta Partners, Clarus Ventures, Delphi Ventures, Endeavour Capital (New Zealand), GBS Venture Partners (Australia), Genentech, No 8 Ventures (New Zealand) and Roche.

Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.

OPAL Therapeutics Pty Limited operates as an immunotherapy development company in Australia. It develops therapies for the treatment of human immunodeficiency virus, Hepatitis C, and chronic infection. OPAL Therapeutics Pty Limited was incorporated in 2005 and is based in Melbourne, Australia.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Hatchtech is an Australian company focused on developing a proprietary technology platform aimed at creating low-toxicity pest control products. The company's patented technology offers a novel mode of action that effectively blocks the hatching of pest species' eggs, making it applicable for managing ectoparasites and other egg-laying pests affecting humans, animals, crops, and built environments. Hatchtech also provides a specialized pharmaceutical product that delivers a single-dose, topical treatment designed to eliminate head lice infestations by killing both the lice and their eggs in one application. Through its innovative approaches, Hatchtech seeks to advance pest control solutions with reduced environmental impact.

Humanigen, Inc. is a clinical-stage biopharmaceutical company based in Burlingame, California, that specializes in the development of proprietary monoclonal antibodies aimed at immunotherapy and oncology treatments. The company’s leading candidate, Lenzilumab, targets granulocyte-macrophage colony-stimulating factor and is currently undergoing Phase Ib/II clinical trials for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. Additionally, Humanigen is developing Ifabotuzumab, which targets the EphA3 receptor and has completed the Phase I portion of a Phase I/II clinical trial for various hematologic malignancies. The company is also working on HGEN005, an anti-EMR1 monoclonal antibody in the pre-clinical stage for eosinophilic diseases. Humanigen has established collaborations, including a clinical partnership with Kite Pharma to study Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma and a research agreement with the Department of Defense to facilitate the development of Lenzilumab for potential emergency use in COVID-19. Formed in 2000, the company was previously known as KaloBios Pharmaceuticals and rebranded as Humanigen in 2017.

Proacta Inc. is a private, clinical-stage, biopharmaceutical company headquartered in San Diego, California. They are focused on addressing unmet needs in the field of cancer with the development of hypoxia-activated prodrugs that target cancer cells. Proacta was founded on intellectual property generated in New Zealand at the University of Auckland and in the United States at Stanford University. Proacta's patent family covers a series of hypoxia-activated prodrugs designed to treat cancer. Expansion of this portfolio is supported by ongoing research at The University of Auckland. PR610 is the lead compound from their pipeline of pro-drugs based on hypoxia-activated tyrosine-kinase inhibitors. These pro-drugs selectively release active tyrosine-kinase inhibitors within the low-oxygen (hypoxic) environment found in many solid tumors. By shifting the release of active drug away from normal tissues and into cancer tissues, these drugs are predicted to be more effective and less toxic than currently available therapies. To date, Proacta has raised $43 million in two private financings. Investors include Alta Partners, Clarus Ventures, Delphi Ventures, Endeavour Capital (New Zealand), GBS Venture Partners (Australia), Genentech, No 8 Ventures (New Zealand) and Roche.

$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

As of October 2010, Phenomix closed down as it was unable to find a partner to pay for is clinical trial bills after Forest Laboratories walked away. Phenomix is a drug discovery and development company building a portfolio of novel therapeutics for the treatment of major human diseases. Phenomix' lead clinical candidate, PHX1149, is a DPP4 inhibitor in phase 2 testing as a once daily oral treatment for type 2 diabetes. Phenomix' second program is directed at the treatment of hepatitis C through inhibition of the NS3/4A viral protease. Phenomix is based in San Diego, California.